Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF | NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $4.28 | Change: +$0.16 | %Change: +3.88%
Volume: 21,960 | Day High/Low: 4.30/4.13 | 52 Week High/Low: 10.36/2.40
View modes: 
0 stars

RE:RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

You haven't missed anything as of yet Oopsy. I think people are just planing for worst case with WF 10. It will all hinge when the official results come out as to what exactly happened with the more
5 stars

RE:RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

I can't believe any of you being so nonchalant about the notion of throwing in the towel on wf10! Was the success of phase1 a fluke? What happened to the arguments made about possibly more
0 stars

RE:RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

The immune group is WF10....of course both will go. The company has stated many times that WF10 was the future for this company. I still feel that something is going on between the two groups.  rate and reply
0 stars

RE:RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

If WF-10 is scrapped, do you really want the immunology group sticking around? I think WF-10 won't be abandoned, but it is of course a possibility. If the drug is truly the dud the share more
4.5 stars

RE:RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

Why in God"s name would they even consider dumping the Immune group ? Already investing millions in research and with one successful trial on the books ....the last one we all know Nuvo should more
1 star

RE:RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

In an earlier post of last week or so, I estimated cash inflows of about $20 million for 2015. it included $0.6 million for P1 royalty. Internal operating margins from manufacturing is quite more
0 stars

This thing has obviously bottomed.

Looks like the bottom is in and all signs are pointing to heading up from here. I see that Seeking Alpha is back promoting it again too with the latest article that was posted here this morning, more
0 stars

RE:RE:Nuvo Research Still Worth The Risk - Seeking Alpha

Scenario 1 reads: "the company decides to scrap WF-10 and therefore Nuvo as a whole." The word "Nuvo" should be changed to "immunology".  rate and reply
1 star

RE:Nuvo Research Still Worth The Risk - Seeking Alpha

The looming decision on what to do with WF-10 should have a major effect on the direction of Nuvo. The article indicates the company would consider focusing on the topical a side if WF-10 more
0 stars

RE:RE:Did You Know?

No idea if they had received the money by the end of December 2014 but they certaintly would have accounted for it in the results. I don't remember seeing any similar restrictions that MNK more
0 stars

RE:Did You Know?

The first paragraph is certainly news to me. Not that it makes a huge difference to the balance sheet, but do you have any idea whether the milestone payment has actually been made? As for the more
0 stars

Did You Know?

In December 2014, a second generic version of Pennsaid launched in the U.S., which entitled the Company to earn an upfront, non-refundable milestone payment of US$0.5 million ($0.6 million). In more
5 stars


I see on Sedar this morning that the AGM will take place on May 13 and the record date March 23rd. There is no mention as to where the meeting will take place - could it be time to have another more
5 stars

Nuvo Research Still Worth The Risk - Seeking Alpha  rate and reply
0 stars

RE:RE:Pennsaid 2%

No doubt Nuvo undersold the rights to Pennsaid 2 . 45 mil buys you two nice homes in West Vancouver . Horizon shareholders are laughing all the way to the bank.  rate and reply
0 stars

RE:Pennsaid 2%

There you go. Horizon knows where Pensaid is heading & they stand before that belief with 45 mil to support it. Thanks for sharing.  rate and reply
1 star

RE:RE:RE:EU sports medicine market..Direct Selling is needed

thanks for that update. If they hit that number, we should get about $7.5 million cad for our manufacturing contract with Horizon.Topside numbers for peak sales have been as high as $100 million. more
0 stars

RE:RE:EU sports medicine market..Direct Selling is needed

Regarding that easy way out, hopefully Pennsaid's 2015 will keep improving enough to make Nuvo feel they undervalued what rights they sold to Horizon. Also, with their balance sheet more
5 stars

Pennsaid 2%

I'm listening to the Horizon Pharma conference call right now. They seem remarkably upbeat about P2 progress so far this year, without giving any specific guidance. Total prescriptions from Dec more
3 stars

RE:EU sports medicine market..Direct Selling is needed

OTC is the dominant sales outlet for sports and soft tissue drugs in Europe. Volraren Gel (Called Emulgel in Europe) leads the topical nsaid market much as it has in the US. Annual sales are of more